吸入激素联合β_2-受体激动剂与联合茶碱治疗哮喘的临床疗效比较

Comparison of inhaled corticosteroids combined with long acting β_2-agonist and with slow-released theophyllines in treatment of asthma

目的观察吸入激素(ICS)联合缓释茶碱(SRT)和ICS联合长效β2-受体激动剂(LABA)治疗哮喘的有效性及其比较。方法将30例中度持续哮喘患者随机分为布地奈德联合缓释茶碱组(S组)及布地奈德联合福莫特罗组(L组)。比较两组患者治疗前后临床改善及呼气峰流速变异率(PEF%)、第1秒用力呼气流速占预计值百分比(FEV1%)变化。结果两组达到良好控制的比例无统计学差异(P>0.05),治疗后两组PEF%较治疗前显著降低(P<0.05),FEV1%较治疗前显著增加(P<0.05),上述两指标改善率两组间无统计学差异(P>0.05)。结论与ICS联合LABA比较,ICS联合SRT治疗哮喘疗效相同且费用低廉。

Objective To compare the effect of inhaled corticosteroids （ICS） combined with slow-released theophyllines （SRT）and ICS combined with long acting β2-agonist （LABA）on asthma. Methods Thirty patients with moderate persistent asthma were randomly treated with budesonide＋SRT （group S,n=15） or budesonide＋formoterol（group L,n=15）for 6 weeks.The peak expiratory flow rate variation （PEFRv）,forced expiratory volume in one second expressed as percentages of predicted normal values（FEV1%）were determined and compared before and after treatment in two groups. Results The proportion of well-controlled asthma patients had no significant difference between two groups（P〉0.05）.After treatment,PEFRv decreased significantly and FEV1% increased significantly in two groups（P〈0.05）,but there was no significant difference in improvement rate of PEFRv and FEV1% between two groups（P〉0.05）. Conclusion ICS＋SRT and ICS＋LABA therapy have the same effects on asthma,but the cost of ICS＋SRT is lower than that of ICS ＋LABA.